Oral Semaglutide Versus Empagliflozin, Sitagliptin and Liraglutide in the UK: Long-Term Cost-Effectiveness Analyses Based on the PIONEER Clinical Trial Programme

[1] Gaede P(1998)Intensive blood–glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) Lancet 352 837-853

[2] Lund-Andersen H(1998)Effect of intensive blood–glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) Lancet 352 854-865

[3] Parving HH(2008)Effect of a multifactorial intervention on mortality in type 2 diabetes N Engl J Med 358 580-591

[4] Pedersen O(2011)Effect of early intensive multifactorial therapy on 5-year cardiovascular outcomes in individuals with type 2 diabetes detected by screening (ADDITION-Europe): a cluster-randomised trial Lancet 378 156-167

[5] Griffin SJ(2018)Management of hyperglycemia in type 2 diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) Diabetes Care 41 2669-2701

[6] Borch-Johnsen K(2019)Evaluation of the long-term cost-effectiveness of once-weekly semaglutide versus dulaglutide for the treatment of type 2 diabetes mellitus in the UK Diabetes Obes Metab 21 611-621

[7] Davies MJ(2019)Once-weekly semaglutide versus once-daily liraglutide for the treatment of type 2 diabetes: a long-term cost-effectiveness analysis in Estonia Diabetes Ther. 10 159-176

[8] Davies MJ(2019)Management of patients with type 2 diabetes with once-weekly semaglutide versus dulaglutide, exenatide ER, liraglutide and lixisenatide: a cost-effectiveness analysis in the Danish setting Diabetes Ther. 10 1297-1317

[9] D’Alessio DA(2019)The management of type 2 diabetes with once-weekly semaglutide versus dulaglutide: a long-term cost-effectiveness analysis in Slovakia Adv Ther. 36 2034-2051

[10] Fradkin J(2013)Clinical inertia in people with type 2 diabetes: a retrospective cohort study of more than 80,000 people Diabetes Care 36 3411-3417

[1] Gaede P(1998)Intensive blood–glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) Lancet 352 837-853

[2] Lund-Andersen H(1998)Effect of intensive blood–glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) Lancet 352 854-865

[3] Parving HH(2008)Effect of a multifactorial intervention on mortality in type 2 diabetes N Engl J Med 358 580-591

[4] Pedersen O(2011)Effect of early intensive multifactorial therapy on 5-year cardiovascular outcomes in individuals with type 2 diabetes detected by screening (ADDITION-Europe): a cluster-randomised trial Lancet 378 156-167

[5] Griffin SJ(2018)Management of hyperglycemia in type 2 diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) Diabetes Care 41 2669-2701

[6] Borch-Johnsen K(2019)Evaluation of the long-term cost-effectiveness of once-weekly semaglutide versus dulaglutide for the treatment of type 2 diabetes mellitus in the UK Diabetes Obes Metab 21 611-621

[7] Davies MJ(2019)Once-weekly semaglutide versus once-daily liraglutide for the treatment of type 2 diabetes: a long-term cost-effectiveness analysis in Estonia Diabetes Ther. 10 159-176

[8] Davies MJ(2019)Management of patients with type 2 diabetes with once-weekly semaglutide versus dulaglutide, exenatide ER, liraglutide and lixisenatide: a cost-effectiveness analysis in the Danish setting Diabetes Ther. 10 1297-1317

[9] D’Alessio DA(2019)The management of type 2 diabetes with once-weekly semaglutide versus dulaglutide: a long-term cost-effectiveness analysis in Slovakia Adv Ther. 36 2034-2051

[10] Fradkin J(2013)Clinical inertia in people with type 2 diabetes: a retrospective cohort study of more than 80,000 people Diabetes Care 36 3411-3417